Illness comorbidity as a biomarker?

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 4, 2012, Pages 221-223

  Anisman, Hymie ^a   Hayley, Shawn ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BRAIN DERIVED NEUROTROPHIC FACTOR;

ADDICTION; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; EDITORIAL; HEART DISEASE; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; NEUROTRANSMISSION; NORADRENERGIC NERVE; OBESITY; PARKINSON DISEASE; PHYSICAL DISEASE; PROGNOSIS; RECURRENT DISEASE; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; STROKE; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 84862591992     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120092     Document Type: Editorial

References (25)

1. Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009;7:357-63.
2. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008;85:1-74.
3. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull 2012 Dec 29. [Epub ahead of print]
4. Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61: 1524-7.
5. Scott TF, Allen D, Price TR, et al. Characterization of major depression symptoms in multiple sclerosis patients. J Neuropsychiatry Clin Neurosci 1996;8:318-23.
6. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54:363-75.
7. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007;65:S253-9.
8. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-97.
9. Chintamani, Gogne A, Khandelwal R, et al. The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer. JRSM Short Rep 2011;2:15.
10. Bilge C, Koçer E, Koçer A, et al. Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. Eur J Phys Rehabil Med 2008;44:13-8.
11. Kim JM, Stewart R, Bae KY, et al. Serotonergic and BDNF genes and risk of depression after stroke. J Affect Disord 2012;136:833-40.
12. Langdon KD, Maclellan CL, Corbett D. Prolonged, 24-h delayed peripheral inflammation increases short- and long-term functional impairment and histopathological damage after focal ischemia in the rat. J Cereb Blood Flow Metab 2010;30:1450-9.
13. McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysi-ology of psychiatric disorders. Ann N Y Acad Sci 2004;1032:1-7.
14. Litteljohn D, Hayley S. Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach. In: Yan Q, editor. Psychoneuroimmunology: methods and protocols. New York (NY): Springer Science, Humana Press; 2012.
15. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - A potential biomarker? Biol Psychiatry 2007; 62:47-54.
16. Wang Y, Cui XL, Liu YF, et al. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1831-5.
17. O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin re-uptake inhibitor therapy. J Psychiatr Res 2007;41:326-31.
18. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-8.
19. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007;18:391-418.
20. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116-27.
21. Klein AB, Williamson R, Santini MA, et al. Bood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuro -psychopharmacol 2011;14:347-53.
22. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012;64:238-58.
23. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167: 1281-8.
24. RIKEN. Advancing personalized medicine: tailoring drugs to fit a patient's genetic predisposition. Science Daily (2012 Feb. 25). Available: www.sciencedaily.com/releases/2012/02/120224 152755.htm (accessed 2012 May 15).
25. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.